Early research (Phase 1)Study completedNCT04945421
What this trial is testing
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
Who this might be right for
NPC
Innovent Biologics (Suzhou) Co. Ltd. 30
Showing 20 of 390 results